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Abstract 
In ergosterol-containing energized yeast plasma membrane vesicles nystatin (5-10 &mg total lipid) caused a massive efRux of pre-accumulated 
arginine while the membrane potential (the principal driving force: -110 mV) decreased by onlv IO-30 mV. Neither the substrate fluxes nor the 
membrane potential was influenced by nyst&in when the p&nease was reconstituted in ergoste;ol-free phospholipid vesicles. The same effect of 
nystatin was found with the reconstituted sugar transporter from Chlorella kessleri. It is suggested that nystatin binding to ergosterol in the vicinity 
of the permease releases the transport protein from its coupling to energy and converts it to a facilitator. 
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1. Introduction 
It is generally accepted that polyene antibiotics such 
as amphothericin B and nystatin may be used as antifun- 
gal agents because they are selectively toxic for fungal 
cells. This selectivity is thought to originate mainly from 
the presence of ergosterol in the fungal plasma mem- 
branes. These antibiotics, at concentrations that inhibit 
growth, are considered to damage yeast cell membranes, 
which results in the leakage of such internal constituents 
as K’, Ca*‘, Mg2+ and PO:-; this is thought to be fol- 
lowed by the inhibition of glycolysis and of protein syn- 
thesis (for review see [l]). 
Recent studies, reviewed by Bolard [2], question the 
assumption that fungal death results from pore forma- 
tion induced by the antibiotics; selective K’ leak being 
the primary event. The lack of correlation between K’ 
leakage and lethality was confirmed with amphothericin 
B and nystatin in C. albicans [3,4] and S. cerevisiue 151. 
In the latter yeast, the release of Mg2’, of nucleic acid 
precursors and of amino acids induced by nystatin has 
been demonstrated (for review see 121). The conclusion 
was that under the influence of nystatin the membranes 
undergo fluidity changes (as opposed to pore formation) 
which contribute somehow to the release of cell constitu- 
ents. 
We have studied the effect of nystatin using an in vitro 
system of yeast plasma membrane vesicles. Nystatin 
*Corresponding author. Fax: (42) (2) 47-2257. 
Abbreviations: Ph,P+, tetraphenylphosphonium ion; TMPD, N,N,N,N’- 
tetramethyl-p-phenylenediamine; CCCP, carbonyl cyanide m-chloro- 
phenyl hydrazone; cytochrome c oxidase, ferrocytochrome-c : oxidore- 
ductase (EC 1.9.3.1). 
seems to affect transport proteins embedded in ergo- 
sterol-containing membranes by releasing them from the 
membrane potential control and converting them to fa- 
cilitated diffusion mediators. 
2. Materials and methods 
2.1. Materials 
The radiolabelled substances L-[U-“‘Clarginine (304 mCi/mmol), 
o-[U-‘4C]glucose (126 mCi/mmol) and tetra-[‘Hlphenylphosphonium 
bromide (33 Ci/mmol) were obtained from Amersham Buchler (Braun- 
schweig). 
Cytochrome c oxidase was isolated from beef heart mitochondria 
according to Yu et al. [6]. 
The lipids L-a-phosphatidylethanolamine (type IX from E. coli, ap- 
proximately 50%) and ergosterol, and miscellaneous chemicals, n-octyl- 
/3-o-glucoside, Ph,PBr, carbonyl cyanide m-chlorphenyl hydrazone, 
horse heart cytochrome c, TMPD, nystatin and arginine were from 
Sigma. 
2.2. Yeast strains 
In this study a transformed strain Saccharomyces cerevisiae RS 453 
(CANI) (ade 2-1, leu2-3,112, his3-11,15, ura52) with a multicopy 
plasmid pWHY bearing CAN1 gene coding for arginine permease [7] 
was used. Some supplementary experiments were carried out with a 
strain Schizosaccharomycespombe transformed by a multicopy plasmid 
pEVP 11 bearing HUPI gene coding for hexose uptake protein in 
Chlorella kessleri (S. pombe TCY 96) [8]. 
2.3. Media and growth condirions 
The yeast strain S. cervisiae RS 453 (CAN 1) was grown on yeast 
minimal medium containing 0.67% yeast nitrogen base without amino 
acids, 2% glucose and required bases and amino acids. The strain 
S. pombe TCY 96 was grown on 2% gluconic acid as a carbon source. 
2.4. Isolation of plasma membranes 
Plasma membranes were isolated from yeast grown at 29°C on a 
rotary shaker. At A,,, = - 0 5 0 8 the cells were harvested, washed and 
broken by shaking with glass beads (diameter 0.45-0.5 mm). Plasma 
membranes were isolated essentially according to Goffeau and Dufour 
[9]. During the isolation the mixture of 0.25 M 4-aminobenzamidine 
dihydrochloride and 0.50 M phenylmethyl sulphonyl floride was re- 
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peatedly added in the amounts of 11100 of the actual isolation solution 
volume. The isolated plasma membranes, suspended in 50 mM potas- 
sium phosphate, pH 6.3, 20% glycerol and 1 mM EDTA, were rapidly 
frozen in liquid nitrogen and stored at -80°C. 
2.5. Preparation of liposomes 
E. coli phospholipid liposomes were prepared as described in Opeka- 
rova et al. [7J. For preparation of ergosterol containing liposomes, the 
chloroform solutions of ergosterol and E. coli phospholipid were mixed 
at a desirable ratio and the subsequent procedure was as above. 
2.6. Reconstitution of cytochrome c oxidase into proteoliposomes 
The procedure used was as described previously [7] with the excep- 
tion that all the buffers used were of pH 6.3 and 1 nmol of cytochrome 
c oxidase was added per 20 mg of total lipids in 1 ml of buffer. 
2.7. Fusion oj’proteoliposomes with yeast plasma membranes 
The proteoliposomes were mixed with yeast plasma membranes at 
a ratio of 20: 1 (lipid/protein) in a final volume of 100-200 ~1. The 
suspension was suplemented with 1 mM MgSO, and rapidly frozen in 
liquid nitrogen. Before use the fused membranes were slowly thawed 
at room temperature and briefly sonicated with a probe-type sonifier 
(Cole-Palmer Instruments Co.). 
2.8. Internal volume 
Internal volume of the vesicles was estimated as described previously 
[7] with the exception that radioactive sucrose was enclosed into the 
vesicles instead of arginine. Use of the noncharged sucrose for this 
purpose excluded the unspecific binding observed with arginine 
probabely due to different lipid composition of the vesicles. 
2.9. Uptake assays 
The uptake experiments were done at room temperature in an open 
magnetically stirred vessel. The vesicles were diluted with 50 mM potas- 
sium phosphate, pH 6.3, containing 1 mM MgSO, to a final concentra- 
tion of 0.05-0.07 mg protein/ml. The energization was started by addi- 
tion of 22 mM ascorbate, 16 ,uM cytochrome c and 180 PM TMPD. 
At zero time, radioactively labelled substance was added. Aliquots of 
30-50 ~1 were withdrawn at intervals and diluted with 100 mM LiCI. 
The suspension was filtered through 0.22~pm pore-size cellulose acetate 
filters (Schleicher and Schuell) and washed with 2.0 ml of LiCI. The 
radioactivity was determined by scintillation counting. 
2.10. Determination of transmembrane electrical potential AY 
The membrane potential (inside negative) was determined from dis- 
tribution of tetra-[3H]pheny1phosphonium cation (Ph,P+) [IO] accord- 
ing to Nerst-Donnan equation: 
AE = -RT/nF x 2.3 log([Ph4P’],,/[Ph4P’]0”J 
where -2.3RTlnF represents approximately 59 mV at room temper- 
ature. 
The calculated values of membrane potential are slightly overesti- 
mated since a correction for nonspecific A3 dependent binding [l I] was 
not included. 
Throughout this study we use membrane potential as a measure of 
energization of the system since it was the main driving force for 
arginine accumulation. The other component of protonmotive force, 
ApH, contributed less than 15% (data not shown). 
2. I I. Protein esiimarion 
Protein was determined by the method of Bradford [12]. 
3. Results and discussion 
The alteration of membrane lipids and/or membrane 
proteins by the polyene antibiotic nystatin can be studied 
with advantage using plasma membrane vesicles pre- 
pared from purified yeast plasma membranes and ex- 
ogenously added lipids of different composition. In a 
recent study on lipid composition of subcellular mem- 
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Fig. 1. Uptake of 20 PM arginine in energized yeast plasma membrane 
vesicles prepared from the membranes of S. cerevisiae RS 453 (CANl) 
fused with E. co/i phospholipid proteoliposomes containing cyto- 
chrome-c-oxidase (0) or with the same proteoliposomes containing in 
addition 12.3% ergosterol(0). At arrow nystatin (9.O&mg lipid) was 
added (o,v). Dashed line represents calculated equilibrium. 
branes of Saccharomyces cerevisiae, Zinser et al. [13] 
showed that in purified plasma membranes the ergo- 
sterol accounts for about 64% of total lipids. It was not 
possible to prepare functioning plasma membrane vesi- 
cles containing this high amount of ergosterol. Only the 
vesicle suspensions containing 30% of ergosterol exhib- 
ited satisfactory membrane potential formation after en- 
ergization and consequently accumulation of arginine. 
The vesicle suspension, however, was quite milky and it 
was difficult to assess what part of the ergosterol had 
been incorporated into vesicles and what had remainded 
in solution. Consequently, the estimated vesicle internal 
volume was 0.5 ,ul/mg lipids, which was only about one 
half of that determined for vesicles prepared from E. coli 
phospholipids (0.9-l .O pl/mg lipids). For comparative 
studies vesicles containing 12.3% of ergosterol were 
found suitable, judging from both the appearance of 
their solution and their internal volume (1.2,Almg lipid). 
Both ergosterol and pure phospholipid vesicles used in 
this study exhibited good transporting activity for argin- 
ine. The Km ranged from 10 to 20pM and V,,,,, amounted 
to 2 nmol/mg protein/min. The arginine accumulation 
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ratios were much higher than those found previously [7]. 
Ergosterol containing vesicles accumulated arginine up 
to go-fold at 100 ,uM arginine outside. This is attributed 
to improvements in membrane isolation procedure used 
in this study (see section 2). 
In Fig. 1 an accumulation of arginine into vesicles 
prepared from E. coli phospholipids and vesicles con- 
taining in addition 12.3% of ergosterol is shown. On 
energization by electron donor system (ascorbate/ 
TMPD/cytochrome c) a comparable membrane poten- 
tial of 100-l 15 mV was formed in both types of vesicles 
(Fig. 2). Generally a somewhat higher accumulation of 
arginine was found in the ergosterol enriched vesicles 
than in those with phospholipids only. It is evident, how- 
ever, that ergosterol is not absolutely necessary for re- 
constitution of arginine transport system. It should be 
noticed, however, that the endogenous ergosterol of the 
purified plasma membrane is present in the vesicles; 
based on the data of Zinser et al. [13] the ergosterol 
content in the ‘phospholipid’ vesicles may amount to 
more than 1%. The vesicles enriched in ergosterol con- 
tain approxemately a 10 times higher amount. The trans- 
port characteristics in both types of vesicles were similar. 
The fluxes of arginine in the vesicles, however, differed 
significantly when nystatin was added (Fig. 1). On addi- 
tion of nystatin a rapid ehlux of accumulated arginine 
was observed from the vesicles enriched in ergosterol, 
which was not the case with ‘phospholipid’ vesicles. The 
extent of the efflux depended on the nystatin/ergosterol 
ratio ranging from 95% of accumulated arginine released 
during 10 min at 70 pg nystatin/mg total lipids to 50% 
at 7 ,ug nystatin/mg lipid. For the sake of comparison of 
the nystatin effect on phospholipid vesicles the amount 
of nystatin was related to total lipids; the external 
amount of ergosterol in ‘ergosterol vesicles’ was the 
same, 12.3%, throughout the study. To minimize further 
additional effects and possible unspecific events the low- 
est amounts of nystatin (5-10 ,ug/mg total lipid) still 
causing the marked effects were used. 
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Fig. 2. Membrane potential formation in energized yeast plasma mem- 
brane vesicles prepared from the membranes of S. cerevisiae RS 453 
(CANl) fused with E. coli phospholipid proteoliposomes containing 
cytochrome-c-oxidase (0) or with the same proteoliposomes containing 
in addition 12.3% ergosterol (0). At arrow nystatin (9.0 pg/rng lipid) 
was added (0,~) or to ergosterol containing vesicles nystatin was added 
concomitantly with Ph,P+ (u). The membrane potential was abbohshed 
by addition of IO ,uM or 1 PM CCCP. 
The observation in Fig. 1 is consistent with the ‘sterol 
hypothesis’ according to which the lethal effect of pol- 
yene antibiotics on eucaryotic cells is due to formation 
of polyene-sterol pores [2]. To see whether the arginine 
efflux proceeds via ergosterol-nystatin pores and to eval- 
uate the overall permeability changes of the system on 
nystatin addition, the accumulation of tetrapheny- 
lphosphonium cation (Ph,P’) in the vesicles was fol- 
lowed. This lipophilic cation is accumulated by simple 
diffusion through lipid bilayer of vesicles in response to 
the electric potential formed. From its final distribution 
the membrane potential can be calculated (see section 2). 
The addition of nystatin did not affect the Ph,P+ accu- 
mulation in energized phospholipid vesicles (hence, nei- 
ther the permeability nor cytochrome c oxidase activity 
were affected) while in energized ergosterol containing 
vesicles nystatin caused a membrane potential drop from 
about -110 to -82 mV during 40 min. Approximately 
the same final membrane potential was formed when 
nystatin was added to the energized vesicles together 
with the membrane potential indicator (Fig. 2). The ob- 
served membrane potential decrease can be explained by 
an increased permeability for K’ [14], which, however, 
most likely is largely compensated for by proton pump- 
ing activity of the cytochrome oxidase. 
It is evident hat no membrane potential could be built 
up in the vesicles if pores causing the arginine leak were 
formed. It is assumed therefore that the efflux observed 
in the presence of nystatin does take place via the argin- 
ine transporter. The membrane potential of -80 mV 
would still be able to drive and maintain approximately 
a 20-fold arginine accumulation, which is not observed, 
however; thus obviously the transporter is not coupled 
to energy anymore; it acts like a facilitator. Passive fluxes 
of a charged hydrophilic molecule like arginine into and 
out of vesicles are very small. Virtually no arginine up- 
take into nonenergized vesicles has been observed (not 
shown). 
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Fig. 3. Uptake of 100fiM arginine in energized yeast plasma membrane 
vesicles prepared from the membranes of Saccharomyces cerevisiae RS 
453 (CANI) fused with E. coli phospholipid proteoliposomes contain- 
ing cytochrome-c-oxidase and 12.3% ergosterol (0). At arrow 1 ,uM 
CCCP (0) or nystatin at concentrations of 9.4 and 6.3 @mg lipid, resp. 
(v) were added. 
When membrane potential was rapidly and completely 
abolished by 10 PM CCCP a considerably slower argin- 
ine leak occured as compared to the nystatin induced 
efflux (not shown), possibly in part reflecting the unidi- 
rectional nature of amino acid transport in yeast (for 
review see [15]). The slow release of arginine from the 
vesicles after addition of 10 ,uM CCCP is in contrast to 
what we observed in our previous study [7]. This discrep- 
ancy can be explained by a different uncoupler/lipid ratio 
employed in this and the previous study, where 10 times 
more lipids were used for the same uncoupler concentra- 
tion. When 1 ,uM CCCP was used for complete uncou- 
pling of the system (Fig. 2) the accumulated arginine was 
retained in the vesicles for at least 30 min and was re- 
leased immediately after addition of nystatin (Fig. 3). 
The high uncoupler/lipid ratio probably causes another 
effect on the vesicles in addition to uncoupling the pro- 
tonmotive force and this will be subjected to further 
studies. The vesicle preparations used throughout this 
study were able to accumulate high internal concentra- 
tion of arginine (up to 8 mM) which might make them 
more fragile. In fact, in some experiments after pro- 
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longed arginine accumulation we observed the spontane- 
ous release of the arginine from the vesicles. 
The evidence given in this study, i.e. the massive re- 
lease of accumulated arginine after addition of nystatin 
to ergosterol vesicles while the overall permeability and 
membrane potential were not considerably changed, 
points to a direct interference of this antibiotic with the 
arginine transporter. The nystatin-carrier interaction 
can be accomplished only when ergosterol as a primary 
binding agent for nystatin is present in sufficiently high 
amounts in the membrane. It can be speculated that an 
interaction of nystatin with the carrier alternates its 
properties in that way that it stops sensing the membrane 
potential (still formed) and is converted to a facilitator. 
Efflux of accumulated sugar from Chlorella kessleri 
[16] and of ol-amino-isobutyric acid from yeast [17] after 
addition of nystatin were observed in vivo. Nystatin in- 
duced sugar efllux from Chlorella cells was interpreted 
as a consequence of the conversion of the active sugar 
transporter into a facilitator. This interpretation was 
based on a countertransport experiment ypical for facil- 
itated diffusion. In the vesicle preparation it was not 
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Fig. 4. Uptake of 18.5 ,uM o-glucose in energized yeast plasma mem- 
brane vesicles prepared from membranes of Schizosaccharotnyces 
pombe TCY 96 fused with E. coli phospholipid proteoliposomes con- 
taining cytochrome-c-oxidase and 12.3% ergosterol (0). At arrow nys- 
tatin (3.5 ,ug/mg lipid) was added (v). 
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The observations reported in this study for the argin- 
ine transporter most likely are more general ones, since 
the same behaviour after addition of nystatin as de- 
scribed here was found with the hexose/H’ cotransporter 
from Chlorella kessleri (Fig. 4). This protein, the gene 
product of the ChZorelZalHUPl gene, was functionally 
expressed in Schizosaccharomyces pombe and reconsti- 
tuted in ergosterol containing proteoliposomes. When 
vesicles not enriched with external ergosterol were used, 
the addition of nystatin did not lead to an efhux of 
glucose (data not shown). On the other hand, the fact 
that the other membrane protein incorporated into the 
system, the mitochondrial cytochrome-c-oxidase, which 
originally comes from an ergosterol-free membrane, is 
affected to a small degree only if at all, may suggest hat 
only eucaryotic membrane proteins are sensitive to the 
antibiotic under study. 
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